Influence of polymer content on stabilizing milled amorphous salbutamol sulphate

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 125-136

  Balani, P N ^a   Wong, S Y ^a   Ng, W K ^b   Widjaja, E ^b   Tan, R B H ^a,b   Chan, S Y ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

Author keywords

Co milling; Polyvinyl pyrrolidone K30; Raman microscopy; Salbutamol sulphate; Stability; X ray powder diffraction

Indexed keywords

EXCIPIENT; HYDROGEN; POLYMER; POVIDONE; SALBUTAMOL SULFATE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; HEAT TREATMENT; HUMIDITY; HYDROGEN BOND; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ALBUTEROL; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; HOT TEMPERATURE; HUMIDITY; PARTICLE SIZE; POLYMERS; POVIDONE; SURFACE PROPERTIES;

EID: 77952868639     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.029     Document Type: Article

References (52)

1. Ambike A.A., Mahadik K.R., Paradkar A. Stability study of amorphous valdecoxib. Int. J. Pharm. 2004, 282:151-162.
2. Aso Y., Yoshioka S., Kojima S. Relationship between water mobility, measured as nuclear magnetic relaxation time, and the crystallization rate of amorphous nifedipine in the presence of some pharmaceutical excipients. Chem. Pharm. Bull. 1996, 44:1065-1067.
3. Bahl D., Bogner R.H. Amorphization of indomethacin by co-grinding with neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm. Res. 2006, 23:2317-2325.
4. Bahl D., Bogner R.H. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin. AAPS Pharm. Sci. Tech. 2008, 9:146-153.
5. Bahl D., Hudak J., Bogner R.H. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm. Dev. Technol. 2008, 13:255-269.
6. Balani P.N., Ng W.K., Tan R.B.H., Chan S.Y. Influence of excipients in co-milling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. J. Pharm. Sci. 2009, doi:101002/jps.21998.
7. Banchero M., Manna L., Ronchetti S., Campanelli P., Ferri A. Supercritical solvent impregnation of piroxicam of PVP at various polymer molecular weights. J. Supercrit. Fluids 2009, 49:271-278.
8. Bhugra C., Pikal M.J. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 2008, 97:1329-1349.
9. Boldyrev V.V., Shakhtshneider T.P., Burleva L.P., Severtsev V.A. Preparation of the disperse systems of sulphathiazole-poly(vinylpyrrolidone) by mechanical activation. Drug Dev. Ind. Pharm. 1994, 20:1103-1114.
10. Brodka-Pfeiffer K., Häusler H., Graβ P., Langguth P. Conditioning following powder micronization: influence on particle growth of salbutamol sulphate. Drug Dev. Ind. Pharm. 2003, 29:1077-1084.
11. Brodka-Pfeiffer K., Langguth P., Graβ P., Häusler H. Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur. J. Pharm. Biopharm. 2003, 56:393-400.
12. Buckton G., Darcy P., Greenleaf D., Holbrook P. The use of isothermal microcalorimetry in the study of changes in crystallinity of spray-dried salbutamol sulphate. Int. J. Pharm. 1995, 116:113-118.
13. Burnett D.J., Thielmann F., Booth J. Determining the critical relative humidity for moisture-induced phase transitions. Int. J. Pharm. 2004, 287:123-133.
14. Chen R., Okamoto H., Danjo K. Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique. Chem. Pharm. Bull. 2008, 56:254-259.
15. Choksi R.J., Shah N.H., Sandhu H.K., Malick A.W., Zia H. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration. J. Pharm. Sci. 2008, 97:2286-2298.
16. Cirri M., Mura P., Rabasco A., Ginés J., Moyano J., Gònzalez-Rodrìguez M. Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers. Drug Dev. Ind. Pharm. 2004, 30:65-74.
17. Columbano A., Buckton G., Wikeley P. A study of the crystallization of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy. Int. J. Pharm. 2002, 237:171-178.
18. Corrigan D.O., Corrigan O.I., Healy A.M. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int. J. Pharm. 2006, 322:22-30.
19. Crowley K., Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 2002, 91:492-507.
20. Dhumal R.S., Biradar S.V., Paradkar A.R., York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int. J. Pharm. 2009, 368:129-137.
21. Friedrich H., Nada A., Bodmeier R. Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug Dev. Ind. Pharm. 2005, 31:719-728.
22. Geeta N., Baggi T.R. An improved spectrophotometric method for the determination of salbutamol sulfate with 3-methylbenzthiazolinone-2-hydrazone. Microchem. J. 1989, 39:137-144.
23. Ghebremeskel A.N., Vemavarapu C., Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm. Res. 2006, 23:1928-1936.
24. 5 particles to nanorods. Cryst. Growth Des. 2008, 8:3661-3665.
25. Gunawan L., Johari G.P., Shanker R.M. Structural relaxation of acetaminophen glass. Pharm. Res. 2006, 23:967-979.
26. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
27. Hancock B.C., Shamblin S.L., Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 1995, 12:799-806.
28. Hyvönen S., Peltonen L., Karjalainen M., Hirvonen J. Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly (l-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone diproprionate. Int. J. Pharm. 2005, 295:269-281.
29. Konno H., Taylor L.S. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci. 2006, 95:2692-2705.
30. Li C.Z., Widjaja E., Chew W., Garland M. Rhodium tetracarbonyl hydride: the elusive metal carbonyl hydride. Angew. Chem. 2002, 41:3784-3789.
31. Mahlin D., Berggren J., Gelius U., Engström S., Alderborn G. The influence of PVP incorporation on moisture-induced surface crystallization of amorphous spray-dried lactose particles. Int. J. Pharm. 2006, 321:78-85.
32. Marini A., Berbenni V., Moioli S., Bruni G., Cofrancesco P., Margheritis C., Villa M. Drug-excipient compatibility studies by physico-chemical techniques. The case of indomethacin. J. Therm. Anal. Cal. 2003, 73:529-545.
33. Marsac P.J., Konno H., Rumondor A.C.F., Taylor L.S. Re-crystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm. Res. 2008, 25:647-656.
34. Miyazaki T., Yoshioka S., Aso Y., Kojima S. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization for amorphous acetaminophen. J. Pharm. Sci. 2004, 93:2710-2717.
35. Ng W.K., Kwek J.W., Tan R.B.H. Anomalous particle shift during post-milling storage. Pharm. Res. 2008, 25:1175-1185.
36. Organisation Internationale de Métrologie Légale (OIML) The Scale of Relative Humidity of Air Certified Against Saturated Salt Solutions 1996, OIML, p. R121.
37. Parrott G.L. Milling of pharmaceutical solids. J. Pharm. Sci. 1974, 63:813-829.
38. g drug. Powder Technol. 2006, 167:20-25.
39. Shakhtshneider T.P. Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation. Sol. St. Ion. 1997, 101-103:851-856.
40. Shakhtshneider T.P., Danède F., Capet F., Willart J.F., Descamps M., Paccou L., Myz S.A., Boldyreva E.V., Boldyrev V.V. Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part II. Cryogenic grinding of piroxicam-polyvinylpyrrolidone mixtures. J. Therm. Anal. Chem. 2007, 89:699-707.
41. Shakhtshneider T.P., Danède F., Capet F., Willart J.F., Descamps M., Paccou L., Surov E.V., Boldyreva E.V., Boldyrev V.V. Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part II. Cryogenic grinding of indomethacin-polyvinylpyrrolidone mixtures. J. Therm. Anal. Chem. 2007, 89:709-715.
42. Tang X.C., Pikal M.J., Taylor L.S. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm. Res. 2002, 19:477-483.
43. Umprayn K., Mendes R.W. Hygroscopicity and moisture adsorption kinetics of pharmaceutical solids: a review. Drug Dev. Ind. Pharm. 1987, 13:653-693.
44. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
45. Watanabe T., Wakiyama N., Usui F., Ikeda M., Isobe T., Senna M. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 2001, 226:81-91.
46. Watanabe T., Hasegawa S., Wakiyama N., Kusai A., Senna M. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int. J. Pharm. 2003, 250:283-286.
47. Widjaja E., Seah R.K.H. Application of Raman microscopy and band-target entropy minimization to identify minor components in model pharmaceutical tablets. J. Pharm. Biol. Anal. 2008, 46:274-281.
48. Widjaja E., Li C.Z., Chew W., Garland M. Band target entropy minimization. A general and robust algorithm for pure component spectral recovery. Anal. Chem. 2003, 75:4499-4507.
49. Yoshioka M., Hancock B.C., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 1995, 84:983-986.
50. Young P.M., Price R. The influence of humidity on the aerosolisation of micronized and SEDS produced salbutamol sulphate. Eur. J. Pharm. Sci. 2004, 22:235-240.
51. Young P.M., Chan H., Chiou H., Edge S., Tee T.H.S., Traini D. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J. Pharm. Sci. 2007, 96:1331-1341.
52. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Del. Rev. 2001, 48:27-42.